CN103191335B - Pharmaceutical composition for treating esophageal achalasia - Google Patents
Pharmaceutical composition for treating esophageal achalasia Download PDFInfo
- Publication number
- CN103191335B CN103191335B CN201310107711.4A CN201310107711A CN103191335B CN 103191335 B CN103191335 B CN 103191335B CN 201310107711 A CN201310107711 A CN 201310107711A CN 103191335 B CN103191335 B CN 103191335B
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- brown
- parched
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating esophageal achalasia. The pharmaceutical composition is applied to the treatment of esophageal achalasia. The pharmaceutical composition is characterized by being prepared from the following raw pharmaceutical materials in proportioning ratio by weight: fingerleaf rodgersflower rhizome, usnea diffracta Vain., poriacocos (Schw.) Wolf, luffa cylindrica (L.) Roem., murraya jasminorage, hordeum vulgare L., setaria italica (L.) Beauv., citrus reticulata Blanco, artemisia japonica Thunb., trachelospermum jasminoides (Lindl.) Lem., radix puerariae and paris polyphylla Sm.. Proved by clinical trials, the pharmaceutical composition has the characteristics of good treatment effect and high safety in the treatment of esophageal achalasia, so that the pharmaceutical composition is worthy of clinical application and popularization.
Description
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of achalasia of esophagus.
Background technology
Achalasia of esophagus is the full esophageal motor dysfunction disease of a kind of constitutional, feature be 1. EB without wriggling.When 2. swallowing, lower esophageal sphincter is not lax or not exclusively lax.3. during tranquillization, LESP power increases.Although achalasia is a kind of benign disease, very big to quality of life, health and aging effects.Due to dysphagia, patient Ke Cai catches as catch can, and comprises position, drinking-water, repeatedly the measure such as to swallow, make patient be ashamed of having dinner in face of everybody, is willing to take food separately, causes mental pressure, have a strong impact on the activities such as social.The cause of disease of primary disease it be unclear that.May with toxin, malnutrition, gene and local inflammation relevant.Whether clinical research finds, spirit misgivings can make infant exacerbation of symptoms, consider because direct stimulation causes Cortical neurons dysfunction, causes maincenter and autonomic nervous dysfunction and falls ill.Cardinal symptom has the vomiting of dysphagia, reflux, chest discomfort or pain.
Current Therapeutic Method comprises medical treatment and surgical intervention two kinds.The medicine that achalasia of cardia medical treatment uses comprises the Nitrates such as nitroglycerin and isosorbide dinitrate; The calcium channel blockers such as nifedipine, Diltiazem and verapamil; Antianxiety drugs; The smooth muscle relaxants such as fourth bromic acid scopolamine.But said medicine clinical efficacy is below 50%, more patient has to carry out surgical intervention, and what wound was smaller is balloon expandable under scope, but expansion often needs repeatedly just can reach alleviation, and relapse rate is very high, and patient suffering is large, and compliance is poor.So, a kind of curative effect of present clinical shortage medical treatment medicine for achalasia of esophagus certainly.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of curative effect certainly and the pharmaceutical composition of the little treatment achalasia of esophagus of side effect.
The technical scheme that the present invention solves its technical problem is: a kind of pharmaceutical composition for the treatment of achalasia of esophagus, it is characterized in that being prepared from by the crude drug of following weight proportion: Rhizoma Rodgersiawe aesculifoliae 10 ~ 30 parts, Radix Artemisiae Japonicae 3 ~ 10 parts, Caulis Trachelospermi 6 ~ 12 parts, Radix Puerariae 6 ~ 12 parts, Rhizoma Paridis 6 ~ 12 parts, Usnea 6 ~ 12 parts, 3 ~ 10 parts, Poria, Pericarpium Citri Reticulatae 6 ~ 12 parts, Retinervus Luffae Fructus 6 ~ 12 parts, Folium Et Cacumen Murrayae 1 ~ 5 part, Fructus Hordei Germinatus (parched to brown) 3 ~ 10 parts, Fructus Setariae Germinatus (parched to brown) 10 ~ 25 parts.
Chinese medicine of the present invention is prepared from by the raw material of following optimum weight part proportioning: Rhizoma Rodgersiawe aesculifoliae 20 parts, Radix Artemisiae Japonicae 6 parts, Caulis Trachelospermi 10 parts, Radix Puerariae 10 parts, Rhizoma Paridis 10 parts, Usnea 10 parts, 6 parts, Poria, Pericarpium Citri Reticulatae 10 parts, Retinervus Luffae Fructus 10 parts, Folium Et Cacumen Murrayae 2 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Fructus Setariae Germinatus (parched to brown) 20 parts.
Wherein said: Rhizoma Rodgersiawe aesculifoliae is the rhizome that saxifragaceae plant ghost lamp is held up.Property is put down, and sour-puckery flavor is nontoxic.Merit can clearing away heat and eliminating dampness, hemostasia and promoting granulation.
Usnea is the thallus (thallus) of Usneaceae Usnea plant USNEA Usnea diffracta (female trailing plants, Herba Cucubali) Usnea diffracta Vain. or Usnea Longissima (Scolopendra Usnea, Herba Stellariae Alsines) U. longissima Ach..Nature and flavor are sweet, flat.Merit can heat-clearing and toxic substances removing, and hemostasia and promoting granulation, pain relieving, liver heat removing and eyesight improving, moves back nebula.
Poria is On Polyporaceae Poria Poriacocos(Schw.) Wolf sclerotium white part.Nature and flavor are sweet, light, flat.GUIXIN, lung, spleen, kidney channel.Merit can promoting diuresis to eliminate damp pathogen, and spleen invigorating, reduces phlegm, mind tranquilizing and the heart calming.
Pericarpium Citri Reticulatae is the dry mature skin of rutaceae orange Citrus reticulata Blanco and variety thereof.Nature and flavor are bitter, pungent, temperature.Return lung, spleen channel.Merit can regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.
Radix Artemisiae Japonicae is the root of feverfew Herba Artemisiae Japonicae Artemisia japonica Thunb..Bitter in the mouth; Micro-sweet; Property is put down.Merit can be dispeled the wind; Tonify deficiency; Parasite killing plants malaria.
Caulis Trachelospermi is the dry zone leaf rattan of apocynaceae plant trachelospermum jasminoide Trachelospermum jasminoides (Lindl.) Lem..Hardship, is slightly cold.GUIXIN, liver, kidney channel.Merit can dispelling wind and removing obstruction in the collateral, and removing heat from blood is subsided a swelling.
Radix Puerariae, Radix Puerariae is the root of leguminous plant Pachyrhizua angulatus.Sweet, pungent, flat.Enter spleen, stomach warp.Merit can be induced sweat, rash, and relaxing muscles and tendons promotes the production of body fluid, antidiarrheal.
Rhizoma Paridis is the rhizome of liliaceous plant Rhizoma Paridis Paris polyphylla Sm..Hardship, is slightly cold.Enter Liver Channel.Merit can heat-clearing and toxic substances removing, detumescence, spasmolytic.
Retinervus Luffae Fructus is the vascular bundle of the dry mature fruit of cucurbitaceous plant Fructus Luffae Luffa cylindrica (L.) Roem..Sweet, flat.Return lung, stomach, Liver Channel.Merit can dredging collateral, invigorates blood circulation, dispels the wind.
Folium Et Cacumen Murrayae is dried leaves and the band leaf twig of rutaceae Folium Et Cacumen Murrayae Murraya exotica L. and Murraya paniculata (L.) Jack. Murraya paniculata (L.) xJack.Pungent, micro-hardship, temperature; Slightly poisonous.Promoting flow of QI and blood dissipating blood stasis, relieving convulsion, removing toxic substances and promoting subsidence of swelling, Eradicates wind is active.
Fructus Hordei Germinatus (parched to brown), for the mature fruit of grass Fructus Hordei Vulgaris Hordeum vulgare L. is through drying of germinateing, fries to burnt brown according to frying method, cooling, sieve dedust bits.Nature and flavor are sweet, flat.Return spleen, stomach warp.Merit can promote qi circulation digestion promoting, and spleen benefiting and stimulating the appetite, moves back newborn relieving distension.
Fructus Setariae Germinatus (parched to brown), for the mature fruit of grass foxtail millet Setaria italica (L.) Beauv. is through drying of germinateing, fries to burnt brown according to frying method.Nature and flavor are sweet, temperature.Return spleen, stomach warp.Merit can help digestion and in, spleen benefiting and stimulating the appetite.
Composition principle: achalasia of esophagus is esophageal motility obstacle disease, show as swallow rear EB without wriggling, Cardiac sphincter relaxes bad.Inventor finds through clinical research for many years, the pathogeny of achalasia of esophagus is " relaxation is abnormal ", namely " esophagus body tension force is not enough; Cardiac sphincter relaxes bad ", can not treat with simple smooth muscle loosening medicine, but start with from the harmony of esophagus and cardia, and draw prescription disclosed by the invention through repetition test deliberation checking.
Compared with prior art, the present invention has following characteristics.
1, prescription is unique: inventor thinks that primary disease is that expectorant folder blood stasis forms, phlegm and blood stasis, and glue work, for suffering from, should be invigorated blood circulation, eliminate the phlegm, eliminating stagnation, dredging collateral go forward side by side, can improve the pathology present situation of the relaxation inaccurate coordination of achalasia of esophagus esophagus and cardia; Avoid the medicine using row irritability in side, its reason is that such medicine can not improve relaxation inaccurate coordination, on the contrary the impairment of YIN due to consumption gas; So get Rhizoma Rodgersiawe aesculifoliae in side, Usnea is monarch, Rhizoma Rodgersiawe aesculifoliae is gentle, is applicable to primary disease and uses, and records and " control damp-heat diarrhea, chronic diarrhea, nebulousurine, leukorrhagia, metrorrhagia, spit blood, epistaxis, fecal blood, sore, incised wound in " Chinese medicine dictionary ".But " confirmation of inventor's clinical experience, heavy dose of Rhizoma Rodgersiawe aesculifoliae has promoting QI to circulate and dispersing the agglomeration of the pathogens function, and does not consume gas, specificly can improve esophageal motility inharmonious; Usnea removing summer-heat is loose clearly, dredging collateral and property is gentle; The capable power of faling apart of described Rhizoma Rodgersiawe aesculifoliae is strong, and Usnea is from granulation promoting from liver heat removing, and the two coordinates, and improves the problem of the relaxation inaccurate coordination of esophagus and cardia on the one hand, can alleviate clinical symptoms on the other hand by dredging collateral.
2, blood system medicine Caulis Trachelospermi, Retinervus Luffae Fructus, Folium Et Cacumen Murrayae are except removing heat from blood and promoting blood circulation effect, all have dredging collateral effect, a medicine multiple-effect, contribute to reducing medicament categories and consumption, do not increase primary disease Liver and kidney burden.
3, manage spleen with removing dampness, cure the disease and ask its source, so prescription Poria of the present invention, Pericarpium Citri Reticulatae dampness removing; And the use of Fructus Hordei Germinatus (parched to brown) and Fructus Setariae Germinatus (parched to brown), be also consider from interior tonifying the spleen gas.
4, Radix Puerariae relaxing muscles and tendons, Rhizoma Paridis spasmolytic, Folium Et Cacumen Murrayae row are altered active, and three medicine combineds effect, in the hope of alleviating cardia achalasia, reduce tractive tension force.
5, prescription is from the unbalance consideration of primary disease relaxation, and Kai Heyou road, gets Radix Artemisiae Japonicae in we, records: Radix Artemisiae Japonicae dosage is 15-30g, for dispeling the wind in " China's book on Chinese herbal medicine "; Tonify deficiency; Parasite killing plants malaria; But inventor's clinical experience finds that low dose of Radix Artemisiae Japonicae has mechanism of qi to open entire merit, the anxiety of the moon and nothing is felt frustrated.
6, medicine material consumption of the present invention is groped to sum up to draw through inventor in a large number, each raw material dosage is for all to have good curative effect in following weight parts scope: Rhizoma Rodgersiawe aesculifoliae amount is larger, inventor studies discovery, only have escalated dose Rhizoma Rodgersiawe aesculifoliae side can have promoting QI to circulate and dispersing the agglomeration of the pathogens function, improve esophageal motility inharmonious; And the dosage of Folium Et Cacumen Murrayae is very little, reason be the Folium Et Cacumen Murrayae of middle heavy dose for narcotic analgesic, and get in we Folium Et Cacumen Murrayae effect be row alter active, without the need to heavy dose, slightly.
Detailed description of the invention
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, crude drug weight proportion: Rhizoma Rodgersiawe aesculifoliae 20g, Usnea 10g, Poria 6g, Pericarpium Citri Reticulatae 10g, Radix Artemisiae Japonicae 6g, Caulis Trachelospermi 10g, Radix Puerariae 10g, Rhizoma Paridis 10g, Retinervus Luffae Fructus 12g, Folium Et Cacumen Murrayae 2g, Fructus Hordei Germinatus (parched to brown) 6g, Fructus Setariae Germinatus (parched to brown) 20g.
The preparation method of embodiment 1 is: Rhizoma Rodgersiawe aesculifoliae, Usnea, Poria, Pericarpium Citri Reticulatae, Radix Artemisiae Japonicae, Caulis Trachelospermi, Radix Puerariae, Rhizoma Paridis, Retinervus Luffae Fructus, Folium Et Cacumen Murrayae, Fructus Hordei Germinatus (parched to brown), Fructus Setariae Germinatus (parched to brown) mixing and water adding are decocted, filtrate is got after 30 minutes, medicinal residues add water continue decoction get filtrate after 20 minutes, twice filtrate merges, and is divided into two parts of morning and evenings to take.
Embodiment 2, crude drug weight proportion: Rhizoma Rodgersiawe aesculifoliae 10 parts, Usnea 6 parts, 3 parts, Poria, Pericarpium Citri Reticulatae 6 parts, Radix Artemisiae Japonicae 3 parts, Caulis Trachelospermi 6 parts, Radix Puerariae 6 parts, Rhizoma Paridis 6 parts, Retinervus Luffae Fructus 6 parts, Folium Et Cacumen Murrayae 1 part, Fructus Hordei Germinatus (parched to brown) 3 parts, Fructus Setariae Germinatus (parched to brown) 10 parts.
Embodiment 3, crude drug weight proportion: Rhizoma Rodgersiawe aesculifoliae 20 parts, Usnea 10 parts, 6 parts, Poria, Pericarpium Citri Reticulatae 10 parts, Radix Artemisiae Japonicae 6 parts, Caulis Trachelospermi 10 parts, Radix Puerariae 10 parts, Rhizoma Paridis 10 parts, Retinervus Luffae Fructus 10 parts, Folium Et Cacumen Murrayae 2 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Fructus Setariae Germinatus (parched to brown) 20 parts.
Embodiment 4, crude drug weight proportion: Rhizoma Rodgersiawe aesculifoliae 30 parts, Usnea 12 parts, 10 parts, Poria, Pericarpium Citri Reticulatae 12 parts, Radix Artemisiae Japonicae 10 parts, Caulis Trachelospermi 12 parts, Radix Puerariae 12 parts, Rhizoma Paridis 12 parts, Retinervus Luffae Fructus 12 parts, Folium Et Cacumen Murrayae 5 parts, Fructus Hordei Germinatus (parched to brown) 10 parts, Fructus Setariae Germinatus (parched to brown) 25 parts.
The Chinese medicine of embodiment 2 ~ 4 can be prepared from by following method:
(1) Radix Puerariae, Usnea, Radix Artemisiae Japonicae coarse powder are extracted volatile oil with vapor distillation respectively, and mixing for standby use after collecting;
(2) Fructus Setariae Germinatus (parched to brown), Fructus Hordei Germinatus (parched to brown) are pulverized 150 mesh sieves, and become fine powder for subsequent use;
(3) Rhizoma Rodgersiawe aesculifoliae, Poria, Pericarpium Citri Reticulatae, Caulis Trachelospermi, Retinervus Luffae Fructus, Rhizoma Paridis, Folium Et Cacumen Murrayae mixing add 10 times of water yields, decoct with water 2 times, each 1 hour, collecting decoction, leave standstill; Then in decocting liquid, add the ethanol of 95% of 3 ~ 4 times of medicinal liquids, leave standstill 15 minutes, then with 3000rpm centrifugal 20 minutes, get precipitation, spraying dry, draw just material;
(4) gained volatile oil in step 1 is sprayed into during step 3 gained just expects, add gained fine powder mixing in step 2, cross 60 mesh sieves, encapsulatedly to form.
Can set every capsules is 0.5g.
The efficient combination of said medicine, coordinates mutually, invigorates blood circulation, eliminates the phlegm, eliminating stagnation, dredging collateral, effectively reach the object for the treatment of achalasia of esophagus, and side effect is less.The above results is clinical data sufficient proof, and interrelated data is as follows.
1 object and method.
1.1 object.
1.1.1 case selection: in March, 2007 ~ 2012 year December is diagnosed as case 60 example of achalasia of esophagus, is outpatient, is divided into matched group, decoction group and Capsules group.Matched group 20 example, age 17 ~ 64(42.32 ± 12.71) year; Decoction group 20 example, age 18 ~ 71(41.89 ± 13.09) year; Capsules group 20 example, age 17 ~ 74(48.48 ± 13.11) year.Compare in sex, age, the state of an illness before three groups of patient treatments, no significant difference (P>0.05), has comparability.
1.1.2 diagnostic criteria: with reference to " Gastroenterology " (the 3rd edition), all cases is all clarified a diagnosis according to medical history, physical examination, X-ray inspection, the inspection of esophagus power.
1.2 method.
1.2.1 Therapeutic Method: matched group takes symptomatic treatment, adopts nifedipine oral.Decoction group with gained decoction oral in the embodiment of the present invention 1,2 times/d.Capsules group with gained capsule oral in the embodiment of the present invention 3,2g/ time, 2 times/d.14d was 1 course for the treatment of, added up curative effect after 2 courses for the treatment of.
1.2.2 criterion of therapeutical effect: with reference to " Gastroenterology ", effective: clinical symptoms, sign turn for the better by and large; Effective: clinical symptoms, sign alleviate; Invalid: clinical symptoms, sign are unchanged.
1.2.3 statistical analysis: SPSS 13.0 carries out statistical analysis.Measurement data t checks, enumeration data chi-square criterion.
2 results.
2.1 Clinical efficacy comparisons: matched group obvious effective rate is 55.00%, decoction group 80.00%, Capsules group 75.00%, decoction group and Capsules group obvious effective rate are apparently higher than matched group (P<0.05).
Before and after 2.2 treatments, esophagus power changes: more all have clear improvement (P<0.05) before and after matched group, decoction group, Capsules group group internal therapy, compare between group, decoction group, Capsules group are obviously better than matched group (P<0.05).After decoction group has 70.00% patient 28d, normal, the Capsules group of the pressure recover of lower esophageal higher-pressure region has the pressure recover of lower esophageal higher-pressure region after 65.00% patient 28d normal.
2.3 3 groups of adverse reactions of patients incidence rates compare: matched group, Capsules group and decoction group all do not occur obvious adverse reaction.
3. conclusion.
This result of study shows, and takes decoction group of the present invention and Capsules group obvious effective rate apparently higher than matched group, and and the incidence rate of untoward reaction is low, illustrates the present invention have in treatment achalasia of esophagus untoward reaction comparatively gently, the higher advantage of safety.
Claims (2)
1. treat a pharmaceutical composition for achalasia of esophagus, it is characterized in that being prepared from by the crude drug of following weight proportion: Rhizoma Rodgersiawe aesculifoliae 10 ~ 30 parts, Radix Artemisiae Japonicae 3 ~ 10 parts, Caulis Trachelospermi 6 ~ 12 parts, Radix Puerariae 6 ~ 12 parts, Rhizoma Paridis 6 ~ 12 parts, Usnea 6 ~ 12 parts, 3 ~ 10 parts, Poria, Pericarpium Citri Reticulatae 6 ~ 12 parts, Retinervus Luffae Fructus 6 ~ 12 parts, Folium Et Cacumen Murrayae 1 ~ 5 part, Fructus Hordei Germinatus (parched to brown) 3 ~ 10 parts, Fructus Setariae Germinatus (parched to brown) 10 ~ 25 parts.
2. a kind of pharmaceutical composition for the treatment of achalasia of esophagus according to claim 1, is characterized in that being prepared from by the crude drug of following weight proportion: Rhizoma Rodgersiawe aesculifoliae 20 parts, Radix Artemisiae Japonicae 6 parts, Caulis Trachelospermi 10 parts, Radix Puerariae 10 parts, Rhizoma Paridis 10 parts, Usnea 10 parts, 6 parts, Poria, Pericarpium Citri Reticulatae 10 parts, Retinervus Luffae Fructus 10 parts, Folium Et Cacumen Murrayae 2 parts, Fructus Hordei Germinatus (parched to brown) 6 parts, Fructus Setariae Germinatus (parched to brown) 20 parts.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310107711.4A CN103191335B (en) | 2013-03-31 | 2013-03-31 | Pharmaceutical composition for treating esophageal achalasia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310107711.4A CN103191335B (en) | 2013-03-31 | 2013-03-31 | Pharmaceutical composition for treating esophageal achalasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103191335A CN103191335A (en) | 2013-07-10 |
| CN103191335B true CN103191335B (en) | 2015-02-25 |
Family
ID=48714268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310107711.4A Expired - Fee Related CN103191335B (en) | 2013-03-31 | 2013-03-31 | Pharmaceutical composition for treating esophageal achalasia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103191335B (en) |
-
2013
- 2013-03-31 CN CN201310107711.4A patent/CN103191335B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 食管-贲门失弛缓症证治探讨;齐贺彬 等;《北京中医》;20070630;第26卷(第06期);345-346 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103191335A (en) | 2013-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998843A (en) | Medicinal composition for treating cholecystitis | |
| CN103495040B (en) | Traditional Chinese medicine composition for treating reflux esophagitis and preparation method of granule formulation thereof | |
| CN103142897B (en) | Medicine used after esophageal achalasia operation | |
| CN105616937A (en) | Traditional Chinese medicine for treating diabetes | |
| CN103191339B (en) | Method for preparing drug for treating pediatric esophageal achalasia | |
| CN103191335B (en) | Pharmaceutical composition for treating esophageal achalasia | |
| CN103142898B (en) | Preparation method of medicine used after esophageal achalasia operation | |
| CN103191336B (en) | Method for preparing drug for treating esophageal achalasia | |
| CN103191338B (en) | Pharmaceutical composition for treating pediatric esophageal achalasia | |
| US20040241259A1 (en) | Herbal ointment and method for constipation treatment | |
| CN115089676B (en) | Application of swertia mileensis-containing traditional Chinese medicine compound composition in preparation of secondary prevention medicine for treating coronary heart disease | |
| CN103341108B (en) | Pharmaceutical composite for treating stress urinary incontinence after prostatectomy | |
| CN105902766A (en) | Peptic ulcer treating medicine and preparation method thereof | |
| CN105998519A (en) | Oral medicine for treating frequent micturition due to pelvic inflammatory disease | |
| CN104958705A (en) | Traditional Chinese medicine for treating oral ulcer | |
| CN115364185A (en) | Traditional Chinese medicine tablet for treating gastrectasia by dredging and reducing stomach qi | |
| CN103142899A (en) | Preparation method of drug for treating spondyloepiphyseal dysplasia | |
| CN103157040A (en) | Pharmaceutical composition for treating multiple osteoenchondroma | |
| CN104173707A (en) | Traditional Chinese medicine ointment for treating globus hysteriocus | |
| CN114129697A (en) | Yang-invigorating soup and preparation method thereof | |
| CN101129981B (en) | Proprietary Chinese medicine for treating courage disease | |
| CN103301378B (en) | Pharmaceutical composition for treating nocturia of children | |
| CN103157042B (en) | Medicament for treating Barrett syndrome | |
| CN103623294B (en) | A kind of preparation method for the treatment of Barrett syndrome medicine | |
| CN103191340A (en) | Drug for nursing osteochondroma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150225 Termination date: 20160331 |